Sygnature Discovery and Proteros Biostructures Establish Strategic Alliance
News Oct 23, 2013
This new alliance adds an integral component to Sygnature’s ‘federated’ CRO Model, which provides fully-integrated drug discovery services to the pharmaceutical industry.
Dr Torsten Neuefeind, CEO, Co-founder at Proteros said, "Sygnature has a growing reputation as a provider of premium integrated drug discovery services. Proteros has worked with Sygnature on a number of drug discovery projects, so we already have an established working relationship. This strategic alliance combines the complementary skills of Proteros and Sygnature Discovery. Proteros will continue to provide X-ray protein structure analysis independently, but will also be able to contribute to fully-integrated drug discovery programmes via Sygnature’s ‘federated’ CRO model. Working closely together on drug discovery projects, we are confident that Proteros and Sygnature can advance clients’ programmes more efficiently and effectively.”
Commenting on the strategic alliance, Dr Simon Hirst, Sygnature’s CEO said, “Proteros has specialist skills in early stage drug discovery that are highly-complementary to our own. Proteros has an outstanding reputation for providing unique and best-in-class technologies for X-ray protein crystallography, kinetic and thermodynamic profiling and tailor-made protein production. Sygnature and Proteros have already collaborated on a number of challenging client projects. The close working relationship that we have established will be cemented through this strategic alliance. With the addition of Proteros to the ‘federated’ CRO Model, it enables Sygnature to offer its customers a world class, fully-integrated drug discovery service where novel compounds can be designed, synthesised and screened in vitro at Sygnature, X-ray protein structure analysis undertaken at Proteros, metabolic liability and toxicity assessed at Cyprotex and then tested at Saretius and Pneumolabs in pharmocodynamic and disease-relevant models. This powerful federation of alliance partners will help accelerate our clients’ drug discovery programmes towards development.”
UT Southwestern researchers have succeeded in neutralizing what they believe is a primary factor in late-onset Alzheimer’s disease, opening the door to development of a drug that could be administered before age 40, and taken for life, to potentially prevent the disease in 50 to 80 percent of at-risk adults.READ MORE